Macular Pigment Lutein Is Antiinflammatory in Preventing Choroidal Neovascularization
- 1 December 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 27 (12), 2555-2562
- https://doi.org/10.1161/atvbaha.107.151431
Abstract
Background— Choroidal neovascularization (CNV) is a critical pathogenesis in age-related macular degeneration, the most common cause of blindness in the developed countries. The aim of the current study was to investigate the effect of lutein supplementation on the development of the murine model of laser-induced CNV together with underlying molecular mechanisms. Methods and Results— Mice were orally pretreated with lutein daily from 3 days before laser photocoagulation untill the end of the study. The index of CNV volume was significantly suppressed by the treatment with lutein, compared with vehicle-treated animals. Lutein treatment led to significant inhibition of macrophage infiltration into CNV and of the in vivo and in vitro expression of inflammation-related molecules including vascular endothelial growth factor, monocyte chemotactic protein −1, and intercellular adhesion molecule-1. Importantly, lutein suppressed IκB-α degradation and nuclear translocation of nuclear factor (NF)-κB p65 both in vivo and in vitro. Additionally, the development of CNV was significantly suppressed by inhibiting NF-κB p65 nuclear translocation, to the levels seen in the lutein treatment. Conclusions— Lutein treatment led to significant suppression of CNV development together with inflammatory processes including NF-κB activation and subsequent upregulation of inflammatory molecules, providing molecular evidence of potential validity of lutein supplementation as a therapeutic strategy to suppress CNV.Keywords
This publication has 33 references indexed in Scilit:
- Interleukin-6 Receptor-Mediated Activation of Signal Transducer and Activator of Transcription-3 (STAT3) Promotes Choroidal NeovascularizationThe American Journal of Pathology, 2007
- Suppression of Choroidal Neovascularization by Inhibiting Angiotensin-Converting Enzyme: Minimal Role of BradykininPublished by Association for Research in Vision and Ophthalmology (ARVO) ,2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Angiotensin II Type 1 Receptor–Mediated Inflammation Is Required for Choroidal NeovascularizationArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Drusen, choroidal neovascularization, and retinal pigment epithelium dysfunction in SOD1-deficient mice: A model of age-related macular degenerationProceedings of the National Academy of Sciences of the United States of America, 2006
- Age-Related Macular Degeneration Is the Leading Cause of Blindness . . .JAMA, 2004
- Macrophage Depletion Inhibits Experimental Choroidal NeovascularizationPublished by Association for Research in Vision and Ophthalmology (ARVO) ,2003
- Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization.Published by Association for Research in Vision and Ophthalmology (ARVO) ,2003
- The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularizationJournal of Leukocyte Biology, 2003
- Prevention of Experimental Choroidal Neovascularization With Intravitreal Anti–Vascular Endothelial Growth Factor Antibody FragmentAmerican Journal of Ophthalmology, 2002